APG Asset Management US’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
– Sell
-33,807
Closed -$8.23M – 161
2024
Q2
$8.23M Sell
33,807
-2,103
-6% -$332K 0.05% 129
2024
Q1
$5.51M Buy
35,910
+11,413
+47% +$1.9M 0.03% 144
2023
Q4
$4.69M Buy
+24,497
New +$4.17M 0.03% 135

Other funds holding ALNY

APG Asset Management US's ALNY Position: Q3 2024 in Review

APG Asset Management US sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2024, closing a stake of 33,807 shares — an estimated $8.23M sold.

APG Asset Management US first reported a position in ALNY in Q4 2023 and held it in 3 quarters. The position peaked at $8.23M in Q2 2024. 567 funds tracked by Wall St. Rank hold ALNY as of Q3 2024.

  • APG Asset Management US reported no remaining Alnylam Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • APG Asset Management US sold 33,807 Alnylam Pharmaceuticals shares in Q3 2024, an estimated $8.23M.
  • APG Asset Management US first reported a position in Alnylam Pharmaceuticals in Q4 2023 and held it in 3 quarters.
  • APG Asset Management US's Alnylam Pharmaceuticals position peaked at $8.23M in Q2 2024.
  • 567 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2024.

Based on APG Asset Management US's 13F filing for Q3 2024, filed 14 Nov 2024.